EP1207155A1 — Drug compositions exhibiting thrombopoietin agonism
Assigned to Shionogi and Co Ltd · Expires 2002-05-22 · 24y expired
What this patent protects
Pharmaceutical compositions containing as an active ingredient compounds of the general formula (I), prodrugs of the same, pharmaceutically acceptable salts of both, or solvates of them and exhibiting thrombopoietin receptor agonism: wherein X 1 is optionally substituted heter…
USPTO Abstract
Pharmaceutical compositions containing as an active ingredient compounds of the general formula (I), prodrugs of the same, pharmaceutically acceptable salts of both, or solvates of them and exhibiting thrombopoietin receptor agonism: wherein X 1 is optionally substituted heteroaryl or the like; Y 1 is -NR A CO-(CH 2 ) 0-2 - or the like (wherein R A is a hydrogen or the like); Z 1 is optionally substituted arylene or the like; and A 1 is a ring represeted by general formula (II) or (III):
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.